Survey of Clinical Protocols for the Use of ¹⁷⁷Lu-PSMA-617 in the United States

Abstract

Although guidelines for the use of ¹⁷⁷Lu-PSMA-617 published by various organizations are important, they do not include all the essential, practical points necessary for a complete institutional protocol. Therefore, a brief survey was performed to assess key components of the ¹⁷⁷Lu-PSMA-617 protocol before, during, and after delivery of therapy. This survey demonstrated the wide variability in many aspects of institutional protocols regarding determination of eligibility for and administration of ¹⁷⁷Lu-PSMA-617 therapy. The real-world protocol details provided here from a variety of institutions may help new and established theranostic programs.